About us

Advancing Cancer Immunology Through Innovation

At the Academy of Cancer Immunology, we are dedicated to transforming the understanding of how immunity plays a pivotal role in cancer treatment and prevention. Established in 1998 with a generous donation from the Cancer Research Institute (CRI), our mission is to drive forward research and foster excellence in the field of cancer immunology.

Our work is focused on the integration of scientific knowledge and cutting-edge research to develop innovative solutions that can combat cancer through immune-based therapies. With over 50 members from 11 countries, we are a global leader in the field of cancer immunology, working collaboratively to make lasting contributions to cancer research and care

Innovative Biotechnology Solutions in Cancer Research

Our approach is built on the latest scientific research and ethical considerations, ensuring the development of safe and effective biotech solutions. We aim to develop breakthrough therapies and tools that empower researchers and healthcare professionals to fight cancer using immune-based strategies.

Through the CRI International Symposia Series, we provide a platform for the latest in cancer vaccine research and antibody-based therapies, ensuring that the most innovative solutions are at the forefront of global research. By staying on the cutting edge, we work to ensure that scientific breakthroughs are translated into real-world benefits for patients.

The Future of ELISA Kits : Why AffiELISA® Stands Out

✽ Understanding ELISA and Its Importance

What is ELISA (Enzyme-Linked Immunosorbent Assay)?
Key applications: Diagnostics, research, drug development
Different types of ELISA: Direct, Indirect, Sandwich, Competitive

Why Choose AffiELISA® ?

✽ Advanced Features

Ultra-high sensitivity & specificity
Faster results with optimized workflow
Reliable and reproducible performance

How to Get Started with AffiELISA

From here

AffiELISA® vs. Traditional ELISA Kits

Feature	AffiELISA®	Standard ELISA
Sensitivity	✅ High	⚠️ Moderate
Speed	✅ Faster	⚠️ Longer incubation
Specificity	✅ Excellent	⚠️ Possible cross-reactivity
Cost-Effectiveness	✅ More value	⚠️ Higher reagent costs

Meet Our Team

Our dedicated professionals are the driving force behind our success. Together, we collaborate on groundbreaking research and explore new opportunities in cancer immunology. Meet the leaders of our Academy :

Tony Fred

Chief Executive Officer

Tony is the visionary founder of the Academy, passionately driving the mission to advance the role of immunity in cancer and support global cancer immunology initiatives.

Mich Stark

Chief Scientific Officer

With years of experience in research and development, Mich is a seasoned biotech executive leading our efforts to bring innovative cancer immunology therapies and research to the forefront.

Aline Turner

Chief Technical Officer

Aline is a leading scientist in biotechnology, heading our team of over 100 researchers dedicated to advancing cancer immunology through innovative technical strategies.

Iris Joe

Chief Scientific Officer

Iris leads our team of biotechnology experts and is focused on advancing the science of cancer immunology through cutting-edge research and development.